news

CUPERTINO, Calif., Nov. 13, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today presented additional safety data and efficacy signals from its Phase 1b clinical trial of DUR-928 in nonalcoholic steatohepatitis (NASH) patients in a poster presentation at The AASLD Liver Meeting Digital Experience ™ (TLMdX) 2020. “The additional safety and efficacy data presented, including improvements in […]

CUPERTINO, Calif., Nov. 10, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Norman Sussman, MD, FAASLD, newly appointed Chief Medical Officer, will host a webinar on the treatment landscape and unmet medical need in treating patients with alcoholic hepatitis (AH), as well as information on DURECT‘ investigational drug candidate, DUR-928, being developed for the treatment

Webcast of Earnings Call Today, November 2nd at 4:30 p.m. ET CUPERTINO, Calif., Nov. 2, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2020 and provided a corporate update. Total revenues were $2.7 million and net loss was $9.3 million for the three months ended

CUPERTINO, Calif., Nov. 2, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on the development of treatments for acute organ injury and chronic liver diseases, today announced it has appointed Norman Sussman, M.D. as its Chief Medical Officer, effective immediately. In this new role, Dr. Sussman will oversee the clinical development of

CUPERTINO, Calif., Oct. 27, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report third quarter 2020 financial results and host a conference call after the market close on Monday, November 2, 2020. Monday, November 2 @ 4:30pm Eastern Time / 1:30 p.m. Pacific TimeToll Free:                             877-407-0784International:                        201-689-8560Conference ID:                    13712508Webcast:                              http://public.viavid.com/index.php?id=142231 About DURECT Corporation DURECT is a biopharmaceutical

CUPERTINO, Calif., Oct. 26, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will partipate in the ROTH Capital Healthcare Event, “Covid-19 Therapeutics in Development,” taking place on Wednesday, October 28, 2020.  The ROTH Healthcare and Biotechnology team are hosting the webinar to discuss key therapies in development to treat COVID disease.  The Webinar

CUERTINO, Calif., Oct. 5, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it will present a poster at The AASLD Liver Meeting Digital Experience ™ (TLMdX) 2020, to be held virtually on November 13-16, 2020.  Topline results from the 4-week Phase 1b clinical study of orally administered DUR-928 in nonalcoholic steatohepatitis (NASH) patients were released previously,

CUPERTINO, Calif., Sept. 30, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President, CEO, Michael H. Arenberg, Chief Financial Officer, and Dr. WeiQi Lin, Executive Vice President of R&D will be participating in a fireside chat hosted by Ed Arce of H. C. Wainwright on Monday, October 5, 2020 from

CUPERTINO, Calif., Sept. 23, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it has dosed the first patient in its randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the safety and efficacy of DUR-928 in hospitalized COVID-19 patients with acute liver or kidney injury. The primary efficacy endpoint is a composite of survival

Phase 2b study in subjects with Alcoholic Hepatitis to evaluate safety and efFIcacy of DUR-928 treatMent (AHFIRM) CUPERTINO, Calif., Sept. 22, 2020 /PRNewswire/ — DURECT Corporation (NASDAQ: DRRX) today announced the study design for the Phase 2b AHFIRM clinical trial of DUR-928 in severe alcoholic hepatitis (AH) patients. AHFIRM is a randomized, double-blind, placebo-controlled, international, multi-center